MannKind Corporation (MNKD)

US — Healthcare Sector
Peers: BMRN  PCVX  LQDA  LEGN  TECH  UTHR  LRMR  DAWN  KNSA  VSTM  IMGN  IMMP  ICPT  ELEV  RLFFD  ACER  NRXPW  KTTA  SABS  INKT  AFMD  ADAP  SGMO 

Automate Your Wheel Strategy on MNKD

With Tiblio's Option Bot, you can configure your own wheel strategy including MNKD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MNKD
  • Rev/Share 0.9806
  • Book/Share -0.1932
  • PB -22.2105
  • Debt/Equity -0.8061
  • CurrentRatio 2.3611
  • ROIC 0.2129

 

  • MktCap 1303872570.0
  • FreeCF/Share 0.0715
  • PFCF 60.0476
  • PE 43.2306
  • Debt/Assets 0.1152
  • DivYield 0
  • ROE -0.2102

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation MNKD Mizuho -- Outperform -- $12 April 10, 2025
Initiation MNKD Wedbush -- Outperform -- $11 Feb. 10, 2025
Initiation MNKD Wells Fargo -- Overweight -- $9 Dec. 20, 2024
Upgrade MNKD RBC Capital Mkts Sector Perform Outperform $7 $10 Dec. 19, 2024
Resumed MNKD Leerink Partners -- Outperform $7 $8 Sept. 9, 2024

News

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
MNKD
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit.

Read More
image for news INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript
MNKD
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

MannKind Corporation (NASDAQ:MNKD ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer Conference Call Participants Olivia Brayer – Cantor Anish Nikhanj – RBC Andreas Argyrides – Oppenheimer & Co. Yun Zhong – Wedbush Anthony Petrone – Mizuho Operator Good morning, and welcome to the MannKind Corporation First Quarter 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on May 08, 2025, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call …

Read More
image for news MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MNKD
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

MannKind (MNKD) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.

Read More
image for news MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
MNKD
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v.

Read More
image for news MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
MNKD
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

Daly to showcase striking “Tired of Pricks?” livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13 Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif.

Read More
image for news MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
MNKD
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & Renshaw Yun Song - Wedbush Securities Operator Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be available for playback …

Read More
image for news MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
MNKD
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics

About MannKind Corporation (MNKD)

  • IPO Date 2004-07-28
  • Website https://www.mannkindcorp.com
  • Industry Biotechnology
  • CEO Dr. Michael E. Castagna Pharm.D.
  • Employees 403

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.